In July 2011, FDA began a pilot program to notify people of drug recalls before they are classified in an effort to expedite notifications of human drug product recalls to the public. FDA is now able to accomplish the goal of expedited notification within the Enforcement Report. These recalls are identified within the Enforcement Report by the label of “Not Yet Classified” in the “Classification” column. It is also possible to search the Enforcement Report for these “Not Yet Classified” recalls using the filter drop down menu. Therefore, as of September 15, 2017 FDA will discontinue the pilot program, and will no longer post drug recalls that are pending classification on this webpage. To see posted recalls that are pending classification go to the weekly Enforcement Report.
Dianabol is not an extremely androgenic steroid, its androgenicity has been structurally reduced, but androgenic side effects are still possible. Such side effects of Dianabol use include acne, accelerated hair loss in those predisposed to male pattern baldness and body hair growth. Most men should not have a problem with such effects, response will be the final dictator, but most will remain clear. Although the odds are in your favor, such effects are brought on by Methandrostenolone being metabolized by the 5-alpha reductase enzyme. This is the same enzyme responsible for the reduction of testosterone to dihydrotestosterone, but the overall conversion here will result in very low amounts of dihydromethandrostenolone. This tells us 5-alpha reductase inhibitors like Finasteride that are often used to combat androgenic side effects will have very little if any affect on Dianabol.
Despite its reduced androgenicity, Dianabol can promote virilization symptoms in women. Such symptoms include body hair growth, a deepening of the vocal chords and clitoral enlargement. It is possible for some women to use this steroid without virilization symptoms with extremely low doses, but the odds are not favorable. Most all women should choose anabolic steroids with less translating androgenic activity to meet their needs.